Media

January 25, 2024 | Publication

Dylan J. Drakes, Abdulraouf M. Abbas, et al.
Cancer Immunology Research (An AACR Journal)
January 25, 2024

January 24, 2024 | In the News

ACIR: Colorectal cancer (CRC) and pancreatic ductal adenocarcinoma (PDAC) have a low survival rate, low infiltration of tumor-specific tumor-infiltrating lymphocytes (TIL), infrequent neoantigen mutations, and checkpoint inhibitors are largely ineffective in PDAC and subtypes of CRC. Common mutations in the oncogenes driver KRAS (mKRAS) however can serve as immunotherapy targets.

January 12, 2024 | In the News

TARGETED ONCOLOGY: The first patient with KRAS-mutated pancreatic ductal adenocarcinoma (PDAC) has been dosed with ELI-002 7P in the phase 2 AMPLIFY-7P study (NCT05726864), according to Elicio Therapeutics, Inc.

January 12, 2024 | In the News

CLINICAL TRIALS ARENA: The study aims to evaluate the antitumor activity of the vaccine in pancreatic ductal adenocarcinoma (PDAC) patients.

January 10, 2024 | In the News

MEDICAL NEWS TODAY: Researchers are reporting that a new vaccine could help prevent the reemergence of colorectal and pancreatic cancer in high-risk people who have previously undergone cancer treatment.

January 9, 2024 | Publication

Shubham Pant, Zev A. Wainberg, et al.
Nature Medicine
January 09, 2024

January 9, 2024 | In the News

INDEPENDENT: A new vaccine has shown “promising” signs of being able to prevent relapse of specific types of pancreatic and bowel cancers for people who have previously had surgery.

January 9, 2024 | In the News

HEALTHDAY: Patients with the most common form of pancreatic cancer could benefit from an experimental therapeutic vaccine, a small new clinical trial shows.

December 14, 2023 | In the News

PHARMA'S ALMANAC: In 2023, the FDA released the draft guidance titled: “Manufacturing Changes and Comparability for Human Cellular and Gene Therapy Products.” This draft guidance provides insight into the FDA’s expectations for cell and gene therapy (CGT) developers regarding manufacturing changes and comparability assessments under chemistry, manufacturing, and control (CMC) requirements.